Showing 1765 results
-
Press release /Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability…
-
Press release /Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
-
Press release /Novartis and Pear Therapeutics to collaborate on prescription software applications aimed to treat patients with schizophrenia and multiple sclerosis Collaboration combines Novartis'…
-
Story /Novartis supports promising young scientists who want to improve their chances to attain advanced science degrees.
-
Story /Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.
-
Press release /Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading…
-
Ad hoc release /Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
-
Press release /Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services…
-
Press release /Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
-
Press release /Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…